Novel drug delivered through nasal spray promising treatment for sleep apnea
Australia: A novel, potent, TASK 1/3 channel antagonist, BAY2586116, in development for obstructive sleep apnoea (OSA), has yielded positive results in research published in CHEST Journal, which tested the drug in people for the first time.
The study tested the drug on 12 people with OSA using either nasal drops, a nasal spray, or a direct application using an endoscope versus a placebo.
The treatment is designed to prevent the narrowing or collapse of the upper airways during sleep, a key factor in OSA; the treatment could prove to be a potential alternative for certain people with OSA to continuous positive airway pressure (CPAP) machines, which can only be tolerated by about half of all OSA sufferers.
"While further rigorous clinical evaluation and testing is required, this is a great first step and should offer some hope to the many people worldwide who suffer from sleep apnoea," says study senior author Professor Danny Eckeart, Director of Flinders University's sleep lab FHMRI: Sleep Health.
"OSA is one of the most common sleep-related breathing disorders, with an estimated one billion sufferers, and when untreated, it is associated with major health and safety consequences. While CPAP machines are effective, tolerance remains a major issue for many, and other treatments, such as dental splints and upper airway surgery, don't always work. This is why we need new treatment options for OSA.
"At the moment, there are no approved drug treatments for OSA. However, with advances in understanding why people get OSA, the potential for effective new medications grows stronger each year."
Monitoring for sleep and airway activity across several sessions, the team found consistent and sustained improvements in the patient's airways staying open throughout sleep, compared to the placebo treatment, regardless of the delivery method used.
"Although a small study, our findings represent the first detailed investigation of this new treatment in people with OSA, with promising results," says study lead author Dr Amal Osman from FHMRI: Sleep Health.
"The drug we tested is designed to target specific receptors expressed on the surface of the upper airways, triggering them more easily to activate the surrounding muscles to keep the airway open during sleep. While there's still a long way to go in clinical testing and development, our study shows targeting these receptors may be a promising avenue for future treatments."
Reference:
Amal M. Osman, Sutapa Mukherjee, Thomas J. Altree, Martina Delbeck, Doris Gehring, Michael Hahn, Tina Lang, Charles Xing, Gerrit Weimann, Danny J. Eckert, Published:November 23, 2022. DOI:https://doi.org/10.1016/j.chest.2022.11.024
